Growth hormone secretagogues (GHS) represent a class of peptides that have attracted substantial preclinical and clinical research attention for their ability to stimulate growth hormone (GH) release from the pituitary gland. Among the most studied GHS compounds are Ipamorelin and Sermorelin, each working through distinct mechanisms that researchers have compared extensively.
Understanding Growth Hormone Secretagogues
The growth hormone axis — involving growth hormone-releasing hormone (GHRH), somatostatin, and ghrelin — is a complex regulatory system that controls GH pulsatile release. Growth hormone secretagogues work by interacting with various components of this axis to influence GH secretion patterns. Research interest stems from GH’s well-established roles in metabolism, body composition, cellular repair, and IGF-1 production.
Sermorelin: A GHRH Analog
Mechanism
Sermorelin (GHRH 1-29 NH₂) is a synthetic analog of the first 29 amino acids of endogenous growth hormone-releasing hormone. It acts at GHRH receptors on pituitary somatotrophs to stimulate GH synthesis and release. Because it mimics the body’s natural GHRH signal, it preserves the pulsatile pattern of GH secretion that researchers consider physiologically important.
Research History
Sermorelin has one of the longest research histories among GHS compounds. It received FDA approval (as Geref) for use in children with growth hormone deficiency before being voluntarily withdrawn from the US market by its manufacturer in 2008 for commercial reasons — not safety concerns. This clinical history provides a substantial body of safety and pharmacokinetic data that researchers have referenced in subsequent GHS studies.
Ipamorelin: A Selective GHRP
Mechanism
Ipamorelin is a pentapeptide growth hormone releasing peptide (GHRP) that acts as a selective agonist of the ghrelin/GHS receptor (GHS-R1a). Unlike some other GHRPs such as GHRP-6 and GHRP-2, research has consistently shown that Ipamorelin demonstrates high selectivity for GH release without significantly stimulating cortisol or prolactin release at research doses — a property that has made it particularly interesting to researchers studying GH secretagogue selectivity.
Selectivity Profile
The selectivity of Ipamorelin has been a key focus of the research literature. Studies published by Novo Nordisk researchers in the late 1990s established its selectivity profile, demonstrating that in porcine models, Ipamorelin stimulated GH release with minimal impact on cortisol, ACTH, and prolactin compared to GHRP-6. This selectivity profile has driven subsequent research interest.
Research Comparison: Ipamorelin vs. Sermorelin
Researchers studying these two compounds have noted several key differences in their mechanisms and profiles:
- Receptor target: Sermorelin acts at GHRH receptors; Ipamorelin acts at ghrelin/GHS-R1a receptors
- Half-life: Sermorelin has a very short half-life (approximately 11 minutes); Ipamorelin’s half-life is approximately 2 hours in animal models
- Selectivity: Ipamorelin demonstrates greater selectivity for GH over other pituitary hormones in preclinical studies
- Combination research: Some researchers have investigated GHRH + GHRP combinations theorizing synergistic effects on GH release — see our CJC-1295 vs. Ipamorelin comparison for more on a related GHRH+GHRP pairing
Research Status
Sermorelin has prior FDA approval history (since withdrawn commercially). Ipamorelin has been developed by Novo Nordisk and has been investigated in clinical trials. Neither is currently FDA-approved for widespread therapeutic use. Both are available for research purposes only.
Disclaimer: This article is for educational purposes only. Ipamorelin and Sermorelin are research chemicals. All research cited pertains to preclinical or limited clinical investigations. Neither compound is approved for human therapeutic use outside of specific regulated contexts.